Close

Kadmon (KDMN) Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Kadmon (KDMN) Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology
(NASDAQ: KDMN) Delayed: 9.50 --0 (-0%)
Previous Close $9.50    52 Week High $11.73 
Open $9.50    52 Week Low $4.44 
Day High $9.50    P/E N/A 
Day Low $9.50    EPS $0.00 
Volume 4,465